C2C12 myoblasts (American Type Culture Collection, USA) were kindly provided by Novartis (Basel, Switzerland). Cells were cultured in Dulbecco's Modified Eagle Medium -GlutaMAX supplemented with 10% fetal bovine serum (FBS) and 1% HEPES (Gibco, UK). Cells were maintained at 37°C in a humidified 5% CO2 cell culture incubator, were passaged using trypsin upon reaching approximately 60% confluency and seeded in appropriate well plates prior differentiation into myotubes. Two days after seeding the medium was replaced by differentiation medium (DM) containing DMEM-Glutamax and 1% HEPES supplemented with 2% horse serum (Gibco, UK) and 0.029 % insulin (stock: 10mg/mL) (Sigma-Aldrich, USA) for three days. They were then starved in DMEM-Glutamax and 1% HEPES supplemented with 2% horse serum (Gibco, UK), without insulin. Myoblasts and myotubes were then treated for 24 hours with DMSO 0.1 %.
Figure Legends
Suppl. Fig. 1 . Oxygen consumption rate (OCR) in C2C12 cells after 1 h drug exposure.
Basal respiration, leak respiration, and maximal respiration are expressed as mean ± SEM of at least three independent experiments. Drug treatments were compared to vehicle control with ANOVA followed by Dunett's test. Significance levels are given as *p < 0.05, **p < 0.01, ***p < 0.001.
Suppl. Fig. 2. SOD2 protein expression in myoblasts and myotubes. Western blots
showing the expression levels of SOD2 and GAPDH. The graph shows the quantification of SOD2 protein expression normalized against GAPDH. Data represent the meanSEM. N= 3. * p < 0.05.
